These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2185787)

  • 1. Tetanus vaccine: present status.
    Wirz M; Gentili G; Collotti C
    Adv Biotechnol Processes; 1990; 13():35-55. PubMed ID: 2185787
    [No Abstract]   [Full Text] [Related]  

  • 2. [Determination of tetanus toxin and toxoid by ELISA using monoclonal antibodies].
    Burkin MA; Sviridov VV; Perelygina OV
    Prikl Biokhim Mikrobiol; 2004; 40(4):478-84. PubMed ID: 15455723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Split tetanus vaccine. Studies on its efficacy and tolerance as compared to adsorbed vaccine].
    Ambrosch F; Wiedermann G
    Fortschr Med; 1984 Aug; 102(29-30):757-9. PubMed ID: 6500445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines.
    Qazi O; Sesardic D; Tierney R; Söderbäck Z; Crane D; Bolgiano B; Fairweather N
    Infect Immun; 2006 Aug; 74(8):4884-91. PubMed ID: 16861677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steps towards the development of a replacement in vitro test for quantification of antibodies to tetanus toxin during potency testing of vaccine.
    Southern J; Clements H; Spenceley L
    Dev Biol Stand; 1996; 86():343. PubMed ID: 8785983
    [No Abstract]   [Full Text] [Related]  

  • 6. The titration of tetanus toxoid (plain).
    Barnes JM; Knight PA; Sheffield F
    Prog Immunobiol Stand; 1970; 4():533-9. PubMed ID: 5488849
    [No Abstract]   [Full Text] [Related]  

  • 7. [In vitro immunization for the production of antibodies to tetanus toxin and toxoid. 1. Systems for the detection of in vitro synthetized specific immunoglobulins. Strategies of test development].
    Kiessig ST; Jahn S; Porstmann T; von Baehr R
    Allerg Immunol (Leipz); 1987; 33(2):79-87. PubMed ID: 2959129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam.
    Hong HA; Ke NT; Nhon TN; Thinh ND; van der Gun JW; Hendriks JT; Kreeftenberg JG
    Bull World Health Organ; 1996; 74(3):275-82. PubMed ID: 8789926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of an in vitro endopeptidase assay for detection of residual toxin activity in tetanus toxoids.
    Leung T; Corran PH; Gee C; Ekong TA; Sesardic D
    Dev Biol (Basel); 2002; 111():327-32. PubMed ID: 12678257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency control of tetanus and diphtheria toxoids, adsorbed, produced in Bulgaria.
    Vrancheva S; Vulchev V; Bachev S
    Prog Immunobiol Stand; 1970; 4():548-52. PubMed ID: 5482199
    [No Abstract]   [Full Text] [Related]  

  • 11. Tetanus prophylaxis.
    Snyder HE
    Surg Gynecol Obstet; 1968 Aug; 127(2):351-2. PubMed ID: 5662855
    [No Abstract]   [Full Text] [Related]  

  • 12. Current concepts in the management of Clostridium tetani infection.
    Brook I
    Expert Rev Anti Infect Ther; 2008 Jun; 6(3):327-36. PubMed ID: 18588497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated antitoxin titers in a man with generalized tetanus.
    Pryor T; Onarecker C; Coniglione T
    J Fam Pract; 1997 Mar; 44(3):299-303. PubMed ID: 9071251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis.
    Robinson K; Chamberlain LM; Schofield KM; Wells JM; Le Page RW
    Nat Biotechnol; 1997 Jul; 15(7):653-7. PubMed ID: 9219268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoids.
    Gupta RK; Siber GR
    Dev Biol Stand; 1996; 86():207-15. PubMed ID: 8785950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on immune response to atoxic fragments of tetanus toxin and its denatured antigen.
    Chiba K
    Kitasato Arch Exp Med; 1982 Dec; 55(3-4):79-118. PubMed ID: 7186080
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro immunization for antibody production against tetanus toxin and toxoid. 3. Recombinant gamma interferon and indomethacin support specific antibody production induced by antigen-pulsed immobilized monocytes.
    Jahn S; Grunow R; Kiesing ST; Volk HD; von Baehr R
    Allerg Immunol (Leipz); 1987; 33(4):239-44. PubMed ID: 2964178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epitope repertoire of human CD4+ lines propagated with tetanus toxoid or with synthetic tetanus toxin sequences.
    Raju R; Diethelm-Okita B; Okita D; Conti-Fine BM
    J Autoimmun; 1996 Feb; 9(1):79-88. PubMed ID: 8845057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the toxin-binding inhibition (ToBI) test for the estimation of the potency of the tetanus toxoïd component in vaccines.
    van der Gun J; Akkermans A; Hendriksen C; van de Donk H
    Dev Biol Stand; 1996; 86():199-206. PubMed ID: 8785949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.